Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY20 results · Jul–Sep 2019
Gufic Biosciences reported revenue from operations of ₹86.03 crore (down 6.9% from Q2 FY19) and net profit of ₹4.30 crore (down 30.4% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 86.03 | 92.42 | −6.9% | 92.39 | −6.9% |
| Other income | 1.61 | 0.70 | +130.7% | 1.02 | +57.6% |
| Total income | 87.64 | 93.12 | −5.9% | 93.41 | −6.2% |
| Profit before tax | 5.65 | 9.52 | −40.6% | 9.19 | −38.5% |
| Net profit for the period | 4.30 | 6.19 | −30.4% | 6.81 | −36.8% |
| EPS, basic (₹) | 0.55 | 0.79 | −30.4% | 0.88 | −37.5% |
| Net margin (%) | 5.0 | 6.7 | 7.4 |
Standalone
- Filed with BSE
- 04 Dec 2019, 13:37 IST
- Board meeting
- 03 Dec 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE